JAMP ENZALUTAMIDE DIN 02515229
Health Canada record
| Active ingredient(s) | ENZALUTAMIDE 40 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L02BB04 ENZALUTAMIDE |
| Original market date | 20-Feb-2026 |
| Current status date | 20-Feb-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating I (2026-09-16).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ENZALUTAMIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02562677 | APO-ENZALUTAMIDE | APOTEX INC | Capsule | ENZALUTAMIDE 40 MG | Marketed |
| 02494736 | AURO-ENZALUTAMIDE | AURO PHARMA INC | Capsule | ENZALUTAMIDE 40 MG | Marketed |
| 02570831 | PMS-ENZALUTAMIDE | PHARMASCIENCE INC | Capsule | ENZALUTAMIDE 40 MG | Approved |
| 02569124 | PRO-ENZALUTAMIDE | PRO DOC LIMITEE | Capsule | ENZALUTAMIDE 40 MG | Approved |
| 02558424 | REDDY-ENZALUTAMIDE | DR REDDY'S LABORATORIES LTD | Capsule | ENZALUTAMIDE 40 MG | Marketed |
| 02407329 | XTANDI | ASTELLAS PHARMA CANADA INC | Capsule | ENZALUTAMIDE 40 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36829 | 2026-02-04 | Abbreviated New Drug Submission (ANDS) |
International API supply for ENZALUTAMIDE
32 active FDA Drug Master Files.
Request a quote for JAMP ENZALUTAMIDE